Tratamiento antiagregante plaquetario personalizado

Translated title of the contribution: Personalized antiplatelet therapy

Paul A. Gurbel, Rahil Rafeedheen, Udaya S. Tantry

Research output: Contribution to journalArticlepeer-review

Abstract

It is well established that high on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is an independent risk factor for ischemic event occurrences in a postpercutaneous coronary intervention patients. However, the precise role of platelet function testing remains debated. Platelet function testing to ensure optimal platelet inhibition has been recommended by some authorities to improve outcomes in patients treated with clopidogrel. Recent prospective, randomized trials of personalized antiplatelet therapy have failed to demonstrate a benefit of platelet function testing in improving outcomes. In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy.

Translated title of the contributionPersonalized antiplatelet therapy
Original languageSpanish
Pages (from-to)480-487
Number of pages8
JournalRevista Espanola de Cardiologia
Volume67
Issue number6
DOIs
StatePublished - Jun 2014

Keywords

  • Genotyping
  • Personalized antiplatelet therapy
  • Platelet function testing
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Personalized antiplatelet therapy'. Together they form a unique fingerprint.

Cite this